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Description

Lung cavitation as a complication of COVID-19 is rare. A 56-year-old male presented with
lung cavitation, small volume hemoptysis, and violaceous discoloration of the right great
toe, 5 weeks after diagnosis with COVID-19 pneumonia. The digital changes were consistent
with previously described microvascular changes called "COVID toe." CT angiography of the
chest was negative for pulmonary embolism but showed a 2.5 x 3.1 x 2.2 cm cavitation within
the right lung. Extensive evaluation for commonly implicated infectious and autoimmune
causes was negative. We concluded that the cavitary lung lesions were likely a complication
of COVID-19 pneumonia and may implicate microangiopathy as an important component of
pathogenesis. This case highlights a rare complication of COVID-19 of which clinicians should
be aware.
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Introduction

A pulmonary cavity is defined as "a gas-filled
space, seen as a lucency or low-attenuation
area, within pulmonary consolidation, a mass,
or a nodule."1 The differential diagnosis of cavitary lung lesions is broad.2,3 Typical infectious
causes include bacterial and fungal etiologies
as well as septic pulmonary emboli. Non-infectious causes include pulmonary infarction,
rheumatologic disease, and malignancy.2,3 Lung
cavitation is not commonly seen in viral pneumonia. Pulmonary cavitation is a rare finding in
the course of COVID-19. We present a case of
cavitary lung lesions that were likely a complication of COVID-19 pneumonia and may implicate microangiopathy as an important component of pathogenesis.

Case Description

A 56-year-old male, who never smoked, had an
onset of fatigue, diarrhea, fever, and headache

5 weeks prior to admission. He was seen in an
outpatient clinic where nasal swab PCR testing
was positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The following week, he developed a dry cough and had a
chest X-ray (CXR) consistent with novel coronavirus disease 2019 (COVID-19) pneumonia
(Figure 1). He was started on prednisone 40 mg
daily for 5 days. One week later, he presented
to the emergency room with lower extremity
pain and swelling. A lower extremity duplex ultrasound showed bilateral distal lower extremity deep venous thromboses (DVTs). He was
treated with apixaban and discharged home.
Three weeks later, he experienced small volume hemoptysis without respiratory distress
and was admitted to the hospital. His oxygen
saturation was 93% on room air. His pulmonary auscultation revealed vesicular breath
sounds without wheezes, rales, or rhonchi. He
was noted to have erythema and edema on
the dorsal surface of the right great toe with
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Figure 1. AP portable CXR 5 weeks after diagnosis with COVID-19 demonstrates bilateral peripheral pulmonary infiltrates.
only minimal associated discomfort (Figure 2),
onset of which he reported within 1 week prior
to presentation, or approximately 4 weeks after
initial symptom onset. It was determined that
this symptom was consistent with "COVID
toe," a previously-described, pernio-like lesion
presenting on the digits and distal extremities.
The CXR showed improvement in the prior pattern of peripheral pulmonary infiltrates (Figure 1).
A computed tomographic angiography (CTA)
of the chest demonstrated patchy peripheral
ground glass opacities, an area of cavitation
measuring 2.5 x 3.1 x 2.2 cm abutting the right
major fissure (Figures 3A-3C) but no evidence
of pulmonary emboli. The patient's laboratory
findings were significant for a C-reactive protein (CRP) of 0.67 mg/dL (normal range <0.29
mg/dL) and an erythrocyte sedimentation rate

(ESR) of 20 mm/hr (reference range 0-15 mm/
hr). Negative studies included: fungal markers
(serum galactomannan and beta-d-glucan);
interferon gamma release assay for latent tuberculosis; anti-nuclear antibody (ANA) and anti-neutrophil cytoplasmic antibody (ANCA); induced sputum for bacterial culture, gram stain,
and acid-fast bacillus (AFB) smear and culture;
human immunodeficiency virus (HIV) antibody;
and transthoracic echocardiogram. Following
a brief admission, the patient demonstrated
clinical improvement and was discharged with
a course of amoxicillin-clavulanate. A CT scan
was obtained 3 months later, which showed a
decrease in the size of the cavitation to 1.1 x 1.4
cm with resolution of ground glass opacities.
He reported his right toe symptoms resolved
approximately 6 to 8 weeks after discharge.

Figure 2. Right great toe shows dorsal erythema and edema, consistent with "COVID toe".
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Figure 3. A-B) Axial chest CT images 5 weeks after diagnosis with COVID-19 show a 2.5 X 3.1 X 2.2
cm cavitary lung lesion in the posterior right upper lobe. C) Axial chest CT images 5 weeks after
diagnosis with COVID-19 show a 2.5 X 3.1 X 2.2 cm cavitary lung lesion in the coronal view.

Discussion

A pulmonary cavity is defined as "a gas-filled
space, seen as a lucency or low-attenuation
area, within pulmonary consolidation, a mass,
or a nodule."1 The differential diagnosis of cavitary lung lesions is broad.2,3 Typical infectious
causes include bacterial and fungal etiologies
as well as septic pulmonary emboli. Non-infectious causes include pulmonary infarction,
rheumatologic disease, and malignancy.2,3
Lung cavitation is not commonly seen in viral pneumonia. Other human coronaviruses,
including SARS-CoV and MERS-CoV, are not
known to cause cavitary lesions.4–6 Cavitary
lesions may be seen with other viral etiologies
such as influenza. However, they are typically
due to superimposed bacterial pneumonia.7
Pulmonary cavitation is a rare finding in the
course of COVID-19, but select cases have
been documented. Selveraj et al. describe a
patient diagnosed with COVID-19 who developed pulmonary cavities on a chest CT 3 weeks
later.8 This case is unique from ours since their
patient had a high titer positive ANA, though
positive ANA have been described in the setting of severe COVID.9 One systematic review
including 4410 COVID-19 patients estimated a
pooled incidence of cavitary lesions to be 0.1%.10
A review by Zoumot et al. included 689 patients
and found a higher incidence of cavitary lesions, comprising 1.7% of all patients admitted
with a diagnosis of COVID-19 and 11% of those
who were admitted to the intensive care unit.11
The patients with cavitary lesions in this study
differ from our patient in that they all received
tocilizumab, were mechanically ventilated, and
were more severely ill.

Various mechanisms have been proposed to
describe how SARS CoV-2 may uniquely cause
cavitary lesions, including cystic degeneration
of consolidations, lung parenchyma caused
primarily by the SARS-CoV-2 virus, bacterial or
fungal coinfection, and small-vessel vasculopathy.12-14 An autopsy study by Ackerman et al.
described widespread microangiopathy with 9
times the prevalence of alveolar capillary microthrombi in SARS-CoV-2 infected lungs when
compared to lungs infected with influenza. This
study also noted intussusceptive angiogenesis and severe endothelial injury, suggesting a
pathogenesis unique to SARS-CoV-2 among
other viral pneumonias.15 In our patient, we
determined exam findings of the right toe were
representative of "COVID toe," given the consistent symptomatology, times of onset, and
resolution similar to what has been described
in previous studies.16,17 Though visually similar to
gout, we assessed that the lack of significant
pain and relatively long duration were highly inconsistent with gout. We believe the presence
of "COVID toe" further provided evidence of
ongoing microvascular injury, as various histologic studies and case reports have described
microvascular injury as a likely cause of this
phenomenon.18,19 As microangiopathy is a known
cause of pulmonary cavitation, we believe this
is a potential mechanism of lung cavitation in
this patient.18

Conclusion

As the SARS-CoV-2 pandemic evolves, so too
must the clinician's understanding of its clinical
presentation. We aim to inform providers of
this uncommon manifestation and to elicit
further discussion and investigation to guide
clinical decision-making.
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